Ozempic sales surge as priced-out Mounjaro patients seek cheaper alternative healthcare Ozempic sales have risen five-fold after a 126 per cent rise in the price of the Mounjaro drug due to pressure from US President Donald Trump. Mounjaro, manufactured by U.S. pharma giant Eli Lilly, has been the UK’s most popular weight loss jab, prescribed to an estimated 90 per cent of the country’s patients. But around [...]
Slim pickings: grocery sales down as Brits turn to weight-loss jabs Retail The growing use of weight-loss drugs like Ozempic could be having an impact on supermarkets’ bottom lines as Brits shy away from more than just unhealthy food. Four per cent of households in the UK now have at least one member using GLP-1, the active ingredient in weight-loss drugs. The share of UK households with [...]
Is your business about to feel the Ozempic squeeze? Opinion Reshaping stomachs with weightloss drugs like Ozempic likely means reshaping some markets (and probably your strategy), says Paul Armstrong Ozempic, Wegovy, and Mounjaro are driving a subtle but undeniable shift in obesity rates across the U.S, showing a 2 per cent drop so far. While it’s too soon to crown these drugs the cure-all, their [...]
Digital health firm explores London listing amid surge in demand for weight-loss jabs June 24, 2024 Digital health business Reset Health is mulling a potential listing on London's stock market as it looks to pounce on the boom in demand for weight-loss jabs.
Ozempic and Wegovy: What happens when a drug goes viral? May 18, 2024 Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?
The Notebook: Where are retail investors putting their money? May 8, 2024 | City Talk Victoria Scholar takes the Notebook pen to talk retail investors, Ozempic's fat profits, and the UK's inflation forecast.